168 related articles for article (PubMed ID: 38004688)
1. Antibiotic Prescriptions in Critically Ill Patients with Bloodstream Infection Due to ESBL-Producing Enterobacteriaceae: Compliance with the French Guidelines for the Treatment of Infections with Third-Generation Cephalosporin-Resistant Enterobacteriaceae-A Multicentric Retrospective Cohort Study.
Le Berre C; Houard M; Vachée A; Georges H; Wallet F; Patoz P; Herbecq P; Nseir S; Delannoy PY; Meybeck A
Microorganisms; 2023 Oct; 11(11):. PubMed ID: 38004688
[TBL] [Abstract][Full Text] [Related]
2. Higher third-generation cephalosporin prescription proportion is associated with lower probability of reducing carbapenem use: a nationwide retrospective study.
Muller A; Bertrand X; Rogues AM; Péfau M; Alfandari S; Gauzit R; Dumartin C; Gbaguidi-Haore H;
Antimicrob Resist Infect Control; 2018; 7():11. PubMed ID: 29387345
[TBL] [Abstract][Full Text] [Related]
3. Non-intravenous carbapenem-sparing antibiotics for definitive treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamase (ESBL) or AmpC β-lactamase: A propensity score study.
Meije Y; Pigrau C; Fernández-Hidalgo N; Clemente M; Ortega L; Sanz X; Loureiro-Amigo J; Sierra M; Ayestarán A; Morales-Cartagena A; Ribera A; Duarte A; Abelenda G; Rodríguez-Baño J; Martínez-Montauti J
Int J Antimicrob Agents; 2019 Aug; 54(2):189-196. PubMed ID: 31075401
[TBL] [Abstract][Full Text] [Related]
4. Beta-lactam/beta-lactamase inhibitors versus carbapenem for bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: systematic review and meta-analysis.
Sfeir MM; Askin G; Christos P
Int J Antimicrob Agents; 2018 Nov; 52(5):554-570. PubMed ID: 30081138
[TBL] [Abstract][Full Text] [Related]
5. Appropriate non-carbapenems are not inferior to carbapenems as initial empirical therapy for bacteremia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a propensity score weighted multicenter cohort study.
Ko JH; Lee NR; Joo EJ; Moon SY; Choi JK; Park DA; Peck KR
Eur J Clin Microbiol Infect Dis; 2018 Feb; 37(2):305-311. PubMed ID: 29177611
[TBL] [Abstract][Full Text] [Related]
6. Use of non-carbapenem antibiotics to treat severe extended-spectrum β-lactamase-producing Enterobacteriaceae infections in intensive care unit patients.
Luyt CE; Faure M; Bonnet I; Besset S; Huang F; Junot H; Hékimian G; Schmidt M; Bréchot N; Combes A; Aubry A; Mayaux J; Chastre J
Int J Antimicrob Agents; 2019 May; 53(5):547-552. PubMed ID: 30742956
[TBL] [Abstract][Full Text] [Related]
7. Combination Therapy with Aminoglycoside in Bacteremiasdue to ESBL-Producing Enterobacteriaceae in ICU.
Benetazzo L; Delannoy PY; Houard M; Wallet F; Lambiotte F; Vachée A; Batt C; Van Grunderbeeck N; Nseir S; Robineau O; Meybeck A
Antibiotics (Basel); 2020 Nov; 9(11):. PubMed ID: 33158238
[TBL] [Abstract][Full Text] [Related]
8. Cefepime vs carbapenems for treating third-generation cephalosporin-resistant AmpC β-lactamase-hyperproducing Enterobacterales bloodstream infections: a multicenter retrospective study.
Hoellinger B; Kaeuffer C; Boyer P; Lefebvre N; Hansmann Y; Robert A; Severac F; Gravet A; Danion F; Ruch Y; Ursenbach A
Int J Infect Dis; 2023 Sep; 134():273-279. PubMed ID: 37453486
[TBL] [Abstract][Full Text] [Related]
9. Clinical Risk Score for Prediction of Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae in Bloodstream Isolates.
Augustine MR; Testerman TL; Justo JA; Bookstaver PB; Kohn J; Albrecht H; Al-Hasan MN
Infect Control Hosp Epidemiol; 2017 Mar; 38(3):266-272. PubMed ID: 27989244
[TBL] [Abstract][Full Text] [Related]
10. Risk factors and outcome of extended-spectrum β-lactamase-producing Enterobacter cloacae bloodstream infections.
Qureshi ZA; Paterson DL; Pakstis DL; Adams-Haduch JM; Sandkovsky G; Sordillo E; Polsky B; Peleg AY; Bhussar MK; Doi Y
Int J Antimicrob Agents; 2011 Jan; 37(1):26-32. PubMed ID: 21075605
[TBL] [Abstract][Full Text] [Related]
11. Role of empirical and targeted therapy in hospitalized patients with bloodstream infections caused by ESBL-producing Enterobacteriaceae.
Falcone M; Vena A; Mezzatesta ML; Gona F; Caio C; Goldoni P; Trancassini AM; Conti C; Orsi GB; Carfagna P; Stefani S; Venditti M
Ann Ig; 2014; 26(4):293-304. PubMed ID: 25001119
[TBL] [Abstract][Full Text] [Related]
12. Appropriateness of empirical antibiotic prescription for bloodstream infections in an emergency department from 2006 to 2018: impact of the spread of ESBL-producing Enterobacterales.
Clemenceau M; Ahmed-Elie S; Vilfaillot A; Chocron R; Compain F; Lebeaux D; Grohs P
Eur J Clin Microbiol Infect Dis; 2022 Jan; 41(1):71-77. PubMed ID: 34553311
[TBL] [Abstract][Full Text] [Related]
13. Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Results From the INCREMENT Cohort.
Palacios-Baena ZR; Gutiérrez-Gutiérrez B; Calbo E; Almirante B; Viale P; Oliver A; Pintado V; Gasch O; Martínez-Martínez L; Pitout J; Akova M; Peña C; Molina Gil-Bermejo J; Hernández A; Venditti M; Prim N; Bou G; Tacconelli E; Tumbarello M; Hamprecht A; Giamarellou H; Almela M; Pérez F; Schwaber MJ; Bermejo J; Lowman W; Hsueh PR; Paño-Pardo JR; Torre-Cisneros J; Souli M; Bonomo RA; Carmeli Y; Paterson DL; Pascual Á; Rodríguez-Baño J;
Clin Infect Dis; 2017 Oct; 65(10):1615-1623. PubMed ID: 29020250
[TBL] [Abstract][Full Text] [Related]
14. Should we consider faecal colonisation with extended-spectrum β-lactamase-producing Enterobacteriaceae in empirical therapy of community-onset sepsis?
Stupica D; Lusa L; Klevišar MN; Terzić S; Pirš M; Premru MM; Strle F
Int J Antimicrob Agents; 2017 Oct; 50(4):564-571. PubMed ID: 28711676
[TBL] [Abstract][Full Text] [Related]
15. Is It Time to Rethink the Notion of Carbapenem-Sparing Therapy Against Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Bloodstream Infections? A Critical Review.
Chastain DB; White BP; Cretella DA; Bland CM
Ann Pharmacother; 2018 May; 52(5):484-492. PubMed ID: 29239220
[TBL] [Abstract][Full Text] [Related]
16. Epidemiology and Burden of Bloodstream Infections Caused by Extended-Spectrum Beta-Lactamase Producing Enterobacteriaceae in a Pediatric Hospital in Senegal.
Ndir A; Diop A; Faye PM; Cissé MF; Ndoye B; Astagneau P
PLoS One; 2016; 11(2):e0143729. PubMed ID: 26867226
[TBL] [Abstract][Full Text] [Related]
17. Audit of carbapenem prescriptions comparing 2 assessment periods.
Lefébure A; Papy E; Rioux C; Diamantis S; Armand-Lefèvre L; Longuet P; Lescure FX; Wolff M; Arnaud P; Lucet JC
Med Mal Infect; 2015 Jul; 45(7):273-8. PubMed ID: 26047686
[TBL] [Abstract][Full Text] [Related]
18. Comparison Between Carbapenems and β-Lactam/β-Lactamase Inhibitors in the Treatment for Bloodstream Infections Caused by Extended-Spectrum β-Lactamase-Producing
Muhammed M; Flokas ME; Detsis M; Alevizakos M; Mylonakis E
Open Forum Infect Dis; 2017; 4(2):ofx099. PubMed ID: 28702469
[TBL] [Abstract][Full Text] [Related]
19. Carbapenem-sparing beta-lactam/beta-lactamase inhibitors versus carbapenems for bloodstream infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a systematic review and meta-analysis.
Zhang H; Xu J; Xiao Q; Wang Y; Wang J; Zhu M; Cai Y
Int J Infect Dis; 2023 Mar; 128():194-204. PubMed ID: 36621752
[TBL] [Abstract][Full Text] [Related]
20. Risk factors and outcomes in non-transplant patients with extended-spectrum beta-lactamase-producing
Xiao T; Yang K; Zhou Y; Zhang S; Ji J; Ying C; Shen P; Xiao Y
Antimicrob Resist Infect Control; 2019; 8():144. PubMed ID: 31467670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
